摘要:
The present invention provides an organic electroluminescent element which comprises: an anode; a cathode; and an organic layer interposed between the anode and the cathodes, wherein the organic layer comprises one or more types of layer from the group consisting of a hole-injection layer, hole-transport layer, light-emitting layer, lifetime enhancement layer, electron-transport layer, and electron-injection layer.
摘要:
The present invention provides an organic electroluminescent element which comprises: an anode; a cathode; and an organic layer interposed between the anode and the cathodes, wherein the organic layer comprises one or more types of layer from the group consisting of a hole-injection layer, hole-transport layer, light-emitting layer, lifetime enhancement layer, electron-transport layer, and electron-injection layer.
摘要:
The present invention pertains to tetracycline derivatives. These tetracycline derivatives can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, viral and parasitic infections as well as inflammatory disorders, such as inflammatory disorders caused by radiation or trauma and inflammatory conditions of the skin.
摘要:
The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms.
摘要:
The present invention pertains, at least in part, to a substituted tetracycline compound of Formula (I): wherein X is CHC(R13VY), CR6 R6, C=CR6 R6, S, NR6, or O; E is NR7dR7β, OR7f or (CH2)o.iC(=W)WR7s; W is O, S, NR711 or CR75R7*; W is O, S or NR7*; These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms.
摘要:
Pharmaceutical compositions comprising at least one compound of the formula (I) and a pharmaceutically acceptable carrier which is useful in a medicine wherein the symbols and substituents have the following meaning -X- is e.g. and Y being e.g. or the pharmaceutically acceptable salts, esters or amides and prodrugs can be applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.